Millennium Management LLC increased its position in shares of Gilead Sciences (NASDAQ:GILD) by 50.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 421,117 shares of the biopharmaceutical company’s stock after acquiring an additional 141,345 shares during the quarter. Millennium Management LLC’s holdings in Gilead Sciences were worth $30,169,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Macquarie Group Ltd. lifted its stake in shares of Gilead Sciences by 26.6% during the third quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock valued at $38,836,000 after acquiring an additional 100,741 shares during the period. Parnassus Investments CA lifted its stake in Gilead Sciences by 2.5% in the fourth quarter. Parnassus Investments CA now owns 19,159,748 shares of the biopharmaceutical company’s stock valued at $1,372,604,000 after buying an additional 464,609 shares during the period. Vicus Capital lifted its stake in Gilead Sciences by 31.5% in the third quarter. Vicus Capital now owns 11,496 shares of the biopharmaceutical company’s stock valued at $931,000 after buying an additional 2,751 shares during the period. Sandy Spring Bank lifted its stake in Gilead Sciences by 5.2% in the third quarter. Sandy Spring Bank now owns 43,234 shares of the biopharmaceutical company’s stock valued at $3,503,000 after buying an additional 2,146 shares during the period. Finally, Schwab Charles Investment Management Inc. lifted its stake in Gilead Sciences by 5.4% in the third quarter. Schwab Charles Investment Management Inc. now owns 4,959,388 shares of the biopharmaceutical company’s stock valued at $401,810,000 after buying an additional 252,556 shares during the period. 78.35% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ GILD opened at $73.70 on Friday. The company has a current ratio of 2.74, a quick ratio of 2.67 and a debt-to-equity ratio of 1.53. The stock has a market cap of $98,675.37, a PE ratio of 8.61, a price-to-earnings-growth ratio of -1.71 and a beta of 1.19. Gilead Sciences has a one year low of $63.76 and a one year high of $89.54.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. The business had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. Gilead Sciences’s quarterly revenue was down 18.7% on a year-over-year basis. During the same period last year, the company earned $2.70 earnings per share. research analysts anticipate that Gilead Sciences will post 6.32 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 29th. Investors of record on Friday, March 16th were issued a dividend of $0.57 per share. The ex-dividend date of this dividend was Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.09%. Gilead Sciences’s dividend payout ratio (DPR) is presently 26.64%.
Several equities analysts have weighed in on the company. Zacks Investment Research raised Gilead Sciences from a “sell” rating to a “buy” rating and set a $85.00 target price on the stock in a research note on Thursday. Credit Suisse Group set a $80.00 target price on Gilead Sciences and gave the company a “hold” rating in a research note on Tuesday. Barclays reissued an “overweight” rating and issued a $95.00 target price (up previously from $90.00) on shares of Gilead Sciences in a research note on Tuesday, March 6th. BidaskClub lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, March 3rd. Finally, Royal Bank of Canada reissued a “buy” rating and issued a $94.00 target price on shares of Gilead Sciences in a research note on Friday, February 23rd. One analyst has rated the stock with a sell rating, nine have issued a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company. Gilead Sciences presently has a consensus rating of “Buy” and an average price target of $88.65.
In related news, CFO Robin L. Washington sold 5,000 shares of the stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $80.31, for a total transaction of $401,550.00. Following the completion of the transaction, the chief financial officer now directly owns 23,749 shares in the company, valued at $1,907,282.19. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Gregg H. Alton sold 25,000 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $83.51, for a total value of $2,087,750.00. Following the transaction, the executive vice president now owns 62,738 shares of the company’s stock, valued at $5,239,250.38. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 308,600 shares of company stock valued at $24,328,226. 1.30% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Gilead Sciences (GILD) Shares Bought by Millennium Management LLC” was first posted by Macon Daily and is owned by of Macon Daily. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://macondaily.com/2018/04/21/gilead-sciences-gild-shares-bought-by-millennium-management-llc.html.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.